Drug Trial Radar · NCT05096481
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 18, 2024
Primary completion
Jun 15, 2028
Study completion Jun 15, 2030
Sponsor
- Lead sponsor
- Nationwide Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Duke University
- First posted
- Oct 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD
Conditions
- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma
- Recurrent Medulloblastoma
Interventions
PEP-CMVBiological
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
TemozolomideDrug
Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Tetanus Diphtheria VaccineBiological
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 4-mo PFS in patients with recurrent medulloblastomaTime frame: 4 months
- 1-yr OS in patients with newly diagnosed DIPGTime frame: one year
- 1-yr PFS in patients with newly diagnosed HGGTime frame: one year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
C.S. Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
St. Louis Children's Hospital
St Louis, Missouri · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Not yet recruiting
Texas Children's Hospital
Houston, Texas · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.